Molecular Partners AG
NASDAQ:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Molecular Partners AG
NASDAQ:MOLN
|
CH |
|
N
|
NC Housing PCL
SET:NCH
|
TH |
|
Eni SpA
NYSE:E
|
IT |
|
Vicor Corp
NASDAQ:VICR
|
US |
|
P
|
Precious Shipping PCL
SET:PSL
|
TH |
|
B&C Speakers SpA
MIL:BEC
|
IT |
|
Digital Information Technologies Corp
TSE:3916
|
JP |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
US |
|
Sylvania Platinum Ltd
LSE:SLP
|
BM |
|
N
|
Namyong Terminal PCL
SET:NYT
|
TH |
|
Extreme Networks Inc
NASDAQ:EXTR
|
US |
|
A
|
ARB Bhd
KLSE:ARBB
|
MY |
|
Sunrun Inc
NASDAQ:RUN
|
US |
|
West Fraser Timber Co Ltd
TSX:WFG
|
CA |
|
Daetwyler Holding AG
SIX:DAE
|
CH |
|
F
|
Fintech SA
WSE:FTH
|
PL |
|
Envirosuite Ltd
ASX:EVS
|
AU |
|
A
|
AB SA
WSE:ABE
|
PL |
|
C
|
Choo Chiang Holdings Ltd
SGX:42E
|
SG |
|
Anghami Inc
NASDAQ:ANGH
|
AE |
|
Philly Shipyard ASA
OSE:PHLY
|
NO |
|
A
|
AstraZeneca PLC
BMV:AZNN
|
UK |
|
Solytech Enterprise Corp
TWSE:1471
|
TW |
|
B
|
Baolong International Co Ltd
TWSE:1906
|
TW |
Bankruptcy Probability
Molecular Partners AG's probability of bankruptcy is hidden . The solvency score is hidden .
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Molecular Partners AG Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CH |
|
Molecular Partners AG
SIX:MOLN
|
125.3m CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Molecular Partners AG's probability of bankruptcy is hidden .
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Molecular Partners AG has total debt of 2.4m CHF. This includes both short-term (0 CHF) and long-term (2.4m CHF) debt.
You can find a full breakdown on its Balance Sheet.
